🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study of Ivonescimab in First-Line ES-SCLC

RecruitingPhase 2Ages 18 Years - 75 YearsAllAkeso
NCT07245446 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). The main questions the study aims to answer are: * What side effects do participants experience from these combination treatments? * How well do the treatments work to shrink tumors? Researchers will compare three groups to see which combination works best. All participants will receive Ivonescimab and chemotherapy (etoposide and carboplatin). The differences are: * Group 1 will also receive an additional drug called AK117. * Group 2 will also receive a different additional drug called Cadonilimab. * Group 3 will receive Ivonescimab and chemotherapy only. Participants will: * Be assigned by chance to one of the thre

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC). * No prior systemic therapy for ES-SCLC. * At least one measurable lesion as defined by RECIST v1.1. * Age 18 to 75 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function. Exclusion Criteria: * Active or untreated central nervous system (CNS) metastases (Treated, stable brain metastases are allowed). * History of severe hypersensitivity to monoclonal antibodies. * Active autoimmune disease requiring systemic treatment within the past 2 years. * Significant cardiovascular disease. * Active hepatitis B or C, or HIV infection. * Interstitial lung disease or non-infectious pneumonitis. * Significant bleeding tendency or risk, including tumor invasion of major blood vessels. * Pregnancy or lactation. * Other active malignancies within 5 years prior to enrollment.
💊

What it tests

  • Ivonescimab
  • Cadonilimab
  • AK117
  • Etoposide
  • Carboplatin (AUC 5)
📍

Where

3 sites
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Shanghai Pulmonary Hospital Affiliated to Tongji University
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy